
ALC Stock Forecast & Price Target
ALC Analyst Ratings
Bulls say
Alcon is a leading global visioncare and surgical company that has recently been spun off from Novartis, and our positive outlook on the stock is based on their strong position in the market, diverse product portfolio, and potential for future growth. Additionally, recent launches such as the Unity platform and PanOptix Pro have helped boost market share in the surgical segment and show potential for continued success. With a solid capital allocation strategy and potential for margin improvement, we believe Alcon has the potential to outperform in the long term.
Bears say
Alcon is experiencing weak demand in its Vision Care segment, driven by slower market growth and increased competition. This, combined with higher costs and limited margin expansion, suggests that the company's stock will remain range-bound. Despite strong new product adoption, including Precision7 and Systane Pro, the overall outlook for Alcon's financials is not positive, with sales and earnings growth expected to be below the company's forecast.
This aggregate rating is based on analysts' research of Alcon Inc. - Registered Shares and is not a guaranteed prediction by Public.com or investment advice.
ALC Analyst Forecast & Price Prediction
Start investing in ALC
Order type
Buy in
Order amount
Est. shares
0 shares